Instalab

Research & Answers

Physician-backed insights to optimize your health and reduce long-term risks.

Ureaplasma Parvum Is Carried by Millions and Almost Never Worth Treating

Somewhere between 20% and 40% of women of reproductive age carry Ureaplasma parvum in their genital tract, and most of them will never know it, never have symptoms, and never need treatment. A major European guideline found no evidence that routine testing and treatment of asymptomatic adults does more good than harm. So why does this tiny bacterium keep showing up in lab results and online forums? Because context matters. In specific situations, particularly certain pregnancies, some infertility cases, and rare invasive infections in vulnerable people, U. parvum shifts from silent freeloader to genuine concern. The challenge is knowing which situation you're actually in.

Letrozole for Fertility: The Cancer Drug That Outperforms the Decades-Old Standard for Ovulation

Letrozole was designed to treat breast cancer. But in head-to-head comparisons against clomiphene, the drug that dominated fertility treatment for over 50 years, letrozole produced higher ovulation rates, higher pregnancy rates, and more live births in women with PCOS. That shift was significant enough for international guidelines to now recommend letrozole as the first-line medication for ovulation induction in PCOS. What makes this especially notable is that letrozole isn't just more effective in key populations. It also tends to produce single-follicle ovulation rather than multiple follicles, which translates to fewer twins and triplets. For anyone weighing fertility treatment options, that combination of better outcomes with lower risk of multiples is worth understanding.